TY - JOUR
T1 - The Next Wave of Influenza Drugs
AU - Shaw, Megan L.
N1 - Publisher Copyright:
© 2017 American Chemical Society.
PY - 2017/10/13
Y1 - 2017/10/13
N2 - Options for influenza therapy are currently limited to one class of drug, the neuraminidase inhibitors. Amidst concerns about drug resistance, much effort has been placed on the discovery of new drugs with distinct targets and mechanisms of action, with great success. There are now several candidates in late stage development which include small molecules targeting the three subunits of the viral polymerase complex and monoclonal antibodies targeting the hemagglutinin, as well as host-directed therapies. The availability of drugs with diverse mechanisms now opens the door to exploring combination therapies for influenza, and the range of administration routes presents more opportunities for treating hospitalized patients.
AB - Options for influenza therapy are currently limited to one class of drug, the neuraminidase inhibitors. Amidst concerns about drug resistance, much effort has been placed on the discovery of new drugs with distinct targets and mechanisms of action, with great success. There are now several candidates in late stage development which include small molecules targeting the three subunits of the viral polymerase complex and monoclonal antibodies targeting the hemagglutinin, as well as host-directed therapies. The availability of drugs with diverse mechanisms now opens the door to exploring combination therapies for influenza, and the range of administration routes presents more opportunities for treating hospitalized patients.
UR - http://www.scopus.com/inward/record.url?scp=85031508050&partnerID=8YFLogxK
U2 - 10.1021/acsinfecdis.7b00142
DO - 10.1021/acsinfecdis.7b00142
M3 - Article
C2 - 28892353
AN - SCOPUS:85031508050
SN - 2373-8227
VL - 3
SP - 691
EP - 694
JO - ACS Infectious Diseases
JF - ACS Infectious Diseases
IS - 10
ER -